Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas
NCT03259503Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2019
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olaparib in diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL) and T-cell non-Hodgkin lymphoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Dose Limiting Toxicities at 30 days. Started Sep 2019; status: completed.
02
Drugs
olaparib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Hodgkin lymphoma (HL)T-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03259503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03259503.